Lille Model - Evidencio

Evidencio uses JavaScript for many of its features. Please enable JavaScript to enable calculations

The Lille Model predicts 6-month mortality and likelihood of corticosteroid response in patients with severe alcoholic hepatitis treated with corticosteroids on day 7 of corticosteroid treatment.

Research authors: Alexandre Louvet, Sylvie Naveau, Marcelle Abdelnour, Marie-Jose Ramond, Emmanuel Diaz, Laetitia Fartoux, Sebastien Dharancy, Frédéric Texier, Antoine Hollebecque, Lawrence Serfaty, Emmanuel Boleslawski, Pierre Deltenre, Valerie Canva, François-René Pruvot, Philippe Mathurin

Version: 1.0.{{ model.microversion }}

Public
Hepatology
{{ modelType }}

V-1.0-10279.26.03.02

(01)08720938015106(8012)v1.0(4326)260302(240)10279

Download the User manual and consult the Intended purpose.

Algorithm
Details
Intended purpose
Electronic label
Release Notes
User manual
{{ toolbarErrorMessage }}

Units

Calculate the result

This algorithm does not calculate automatically.
Please provide all the needed parameters and press calculate.

Set more parameters to perform the calculation

The Lille Score is

Set more parameters to perform the calculation

The Lille Score is

Result interval {{ additionalResult.min }} to {{ additionalResult.max }}

Conditional information

Your text input(s) have been changed. Please update your result. Update

PRO

Note

Notes are only visible in the result download and will not be saved by Evidencio

Calculations alone should never dictate patient care, and are no substitute for professional judgement. See our full disclaimer.

Underlying algorithms Part of

Additional information

Details

Algorithm author

Evidencio

Algorithm ID

10279

Version

1.0.{{ model.microversion }}

Revision date

2026-03-02

Specialty

Hepatology

Algorithm type

R-Script algorithm ^{(Calculation)}

MeSH terms

Alcoholic Hepatitis

Status

Public

Condition	Formula

Study characteristics

Additional information

From Louvet et al:

Inclusion Criteria and Corticosteroid Protocol. All patients with a DF ≥ 32 or encephalopathy at admission were treated by corticosteroids if they fulfilled the following criteria: (1) a history of alcoholism; (2) liver chemistry suggestive of AH; (3) the absence of uncontrolled infection or recent gastrointestinal hemorrhage (<15 days); (4) transjugular liver biopsy, which was carried out for all patients. Histological diagnosis of AH was based on the presence of hepatocellular necrosis and infiltration of polymorphonuclear leukocytes. We excluded patients with active peptic ulcers, neoplasms, positive test for hepatitis B surface antigen, and human immunodeficiency virus antibodies. Patients were treated in all centers using the same treatment protocol. Prednisolone was given in a single dose of 40 mg each morning for 28 days. Patients unable to take oral medication received intravenous infusions of 32 mg methylprednisolone. In the validating cohort, only patients with a DF ≥ 32 were treated.

Exploratory Cohort of Severe AH. For development of the model, 320 patients were included from July 1990 to October 2001 in Beaujon, Beclere, and Saint-Antoine Hospitals and from October 2001 to October 2003 in the Lille Hospital.

Validating Cohort of Severe AH. We validated the performance of the Lille model in an independent prospective cohort of patients hospitalized in Lille and Bethune Hospitals for severe AH treated by corticosteroids. Validation and comparison of models were performed prospectively from November 2003 to April 2005 in all patients (n =118) admitted. International normalized ratio (INR) was measured in this validating cohort to compare the Lille model with the MELD score calculated using the formula described by Dunn et al.

See below for a figure from Mathurin et al. showcasing the difference in response to corticosteroid treatment in patients from different risk categories, clearly showing increased survival from corticosteroid treatment in some but not all risk groups

Study Population

Total population size: 295

Males: {{ model.numberOfMales }}

Females: {{ model.numberOfFemales }}

Continuous characteristics

Name	LL	Median	UL	Unit
Age	28.2	49.7	78	years
Bilirubin	32	210	877	μmol/L
Prothrombin time	13.5	19.5	32	seconds
Albumin	11	27	49	g/L
Serum creatinine	0.32	0.8	6.7	mg/dL
AST	15	95	504	IU/L
white blood cells	2200	10800	64000	no/mm^3
Daily Alcohol intake	30	120	400	g/day
Evolution of Bilirubin between day 0 and day 7	355	32.2	403	μmol/L
Child-Pugh Score	7	10	15	points
Maddrey Function	23.2	47.5	144.6	(DF)

Categorical characteristics

Name	Subset / Group	Nr. of patients
Presence of ascites	Yes	203
Presence of ascites	No	55
Presence of ascites	Unknown	37
Encephalopathy	Yes	78
Encephalopathy	No	217

Supporting Publications

Title or description

Related files

Preview

Name

This algorithm has been certified as a medical device

V-1.0-10279.26.03.02

Medical Devices

Evidencio offers CE-certified MDSWs (Medical Device Software) of both widely adopted and new ground breaking algorithms. Evidencio provides an easy, sustainable and scalable way to be compliant in your use of algorithms and AI for clinical decision support, shared decision making, patient monitoring, etc.

The algorithm Lille Model has been certified as a medical device and is only available to qualified Evidencio subscribers.

In general, the prediction models and algorithms that are freely available on Evidencio are intended for research and education purposes only.

Some of the medical prediction models and algorithms that are available on Evidencio are classified as (e.g. CE) Medical Devices.
This implies that these algorithms may be used for clinical decision making by medical professionals, as long as this use strictly adheres to the algorithm’s Intended Purpose statements.

{{ collapsed.intendedUse ? $t('show_intended_use') : $t('hide_intended_use') }}

In order for Evidencio to comply with legislation regarding the use of medical devices, we must monitor use of these medical devices to the greatest extent to prevent mis-use. Therefore, the Medical Devices on Evidencio can only be used by named Evidencio Subscribers.

To access this algorithm you will need an Evidencio Pro Subscription

Visit our library for more prediction algorithms

Already have an account? Log in Go back Sign Up

Evidencio Pro

€9,99 / Month

This functionality is reserved for Pro subscribers.
Please support us by registering as Evidencio Pro.

Clinical & Commercial use licence

Create licenced algorithms

Unlimited Patient specific reports

Create direct access for peer reviewers.

Use licensed algorithms

Cancel at any time

For a complete list of all the benefits, see Services

Looking to manage Teams Or EHR integration? Get in touch with our team.

Signup for Pro subscription

Select the version you want to duplicate Are you sure you want to duplicate this algorithm?

Please sign in to enable Evidencio print features

In order to use the Evidencio print features, you need to be logged in.
If you don't have an Evidencio Community Account you can create your free personal account at:

https://www.evidencio.com/registration

Printed results - Examples {{ new Date().toLocaleString() }}

Evidencio Community Account Benefits

With an Evidencio Community account you can:

Create and publish your own prediction algorithms.
Share your prediction algorithms with your colleagues, research group, organization or the world.
Review and provide feedback on algorithms that have been shared with you.
Validate your algorithms and validate algorithms from other users.
Find algorithms based on Title, Keyword, Author, Institute, or MeSH classification.
Use and save prediction algorithms and their data.
Use patient specific protocols and guidelines based on sequential algorithms and decision trees.
Stay up-to-date with new algorithms in your field as they are published.
Create your own lists of favorite algorithms and topics.

A personal Evidencio account is free, with no strings attached!
Join us and help create clarity, transparency, and efficiency in the creation, validation, and use of medical prediction algorithms.

Disclaimer: Calculations alone should never dictate patient care, and are no substitute for professional judgement.

Browse

Create

Browse

Create

Login

Sign Up

{{ section.title }}

Calculate the result

The Lille Score is

Conditional information

Details

Study characteristics

Additional information

Study Population

Continuous characteristics

Categorical characteristics

Supporting Publications

Related files

This algorithm has been certified as a medical device

Select the version you want to duplicate Are you sure you want to duplicate this algorithm?

Non-medical device

Please sign in to enable Evidencio print features

Printed results - Examples {{ new Date().toLocaleString() }}

Evidencio Community Account Benefits

{{ variable.title }}

Result display

	Evidencio B.V., Irenesingel 19, 7481 GJ Haaksbergen, The Netherlands
	V-1.0-10279.26.03.02
	(01)08720938015106(8012)v1.0(4326)260302(240)10279
	Download the User manual
	Medical device In vitro diagnostic medical device